As of press time, the stock rose more than 12%, reporting USD 16.93.
According to Choicely Finance, on Monday, Novavax (NVAX.US) saw a rise in the stock price, with a gain of over 12% to report at USD 16.93, and a market capitalization of over USD 2.4 billion. On the news front, the advisors of the US Food and Drug Administration (FDA) will vote to decide whether to recommend that COVID-19 vaccines for 2024-25 be targeted against the JN.1 variant, which is the most significant variant of this year. Last month, Novavax stated that it could only provide COVID-19 vaccines in the US this fall once regulatory agencies approved the JN.1 variant of the vaccine that they started producing.